Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaper › Review › Research › peer-review
Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaper › Review › Research › peer-review
}
TY - JOUR
T1 - Management of thyrotoxicosis during pregnancy
AU - Andersen, Stine Linding
AU - Knøsgaard, Louise
PY - 2020/7
Y1 - 2020/7
N2 - Thyrotoxicosis during pregnancy should be adequately managed and controlled to prevent maternal and fetal complications. The evaluation of thyroid function in pregnant women is challenged by the physiological adaptations associated with pregnancy, and the treatment with antithyroid drugs (ATD) raises concerns for the pregnant woman and the fetus. Thyrotoxicosis in pregnant women is mainly of autoimmune origin, and the measurement of thyroid stimulating hormone-receptor antibodies (TRAb) plays a key role. TRAb helps to distinguish the hyperthyroidism of Graves’ disease from gestational hyperthyroidism in early pregnancy, and to evaluate the risk of fetal and neonatal hyperthyroidism in late pregnancy. Furthermore, the measurement of TRAb in early pregnancy is recommended to evaluate the need for ATD during the teratogenic period of pregnancy. Observational studies have raised concern about the risk of birth defects associated with the use of ATD in early pregnancy and challenged the clinical management and choice of treatment.
AB - Thyrotoxicosis during pregnancy should be adequately managed and controlled to prevent maternal and fetal complications. The evaluation of thyroid function in pregnant women is challenged by the physiological adaptations associated with pregnancy, and the treatment with antithyroid drugs (ATD) raises concerns for the pregnant woman and the fetus. Thyrotoxicosis in pregnant women is mainly of autoimmune origin, and the measurement of thyroid stimulating hormone-receptor antibodies (TRAb) plays a key role. TRAb helps to distinguish the hyperthyroidism of Graves’ disease from gestational hyperthyroidism in early pregnancy, and to evaluate the risk of fetal and neonatal hyperthyroidism in late pregnancy. Furthermore, the measurement of TRAb in early pregnancy is recommended to evaluate the need for ATD during the teratogenic period of pregnancy. Observational studies have raised concern about the risk of birth defects associated with the use of ATD in early pregnancy and challenged the clinical management and choice of treatment.
KW - antithyroid drugs
KW - hyperthyroidism
KW - methimazole
KW - propylthiouracil
KW - TRAb
UR - http://www.scopus.com/inward/record.url?scp=85081956273&partnerID=8YFLogxK
U2 - 10.1016/j.beem.2020.101414
DO - 10.1016/j.beem.2020.101414
M3 - Review
C2 - 32199749
AN - SCOPUS:85081956273
VL - 34
JO - Best Practice & Research: Clinical Endocrinology & Metabolism
JF - Best Practice & Research: Clinical Endocrinology & Metabolism
SN - 1521-690X
IS - 4
M1 - 101414
ER -